German pharmaceuticals giant UCB Pharma GmbH hit Fifteen generic-drug manufacturer (Accord, Alembic, Amneal, Aurobindo, Breckenridge, Glenmark, Hetero, Mylan, Ranbaxy, Sandoz, ScieGen, Sun Pharma, Watson and Zydus) with suits in Delaware federal court of infringing one of its patents by seeking approval for generic forms of UCB's epilepsy drug Vimpat® (Lacosamide).
Plaintiffs UCB Pharma actions relates to generics that they infringed one or more claims of the Reissued Patent No. RE 38,551 (“the ‘551 patent”) by filing the ANDA seeking approval for the commercial manufacture, use, offer for sale, sale and/or import of Vimapt before the expiration of the ’551 patent.
Patents in suit:
RE 38,551: “Anticonvulsant enantiomeric amino acid derivatives” by Kohn. Prosecuted by Scully, Scott, Murphy & Presser. Includes 13 claims (1 indep.). Was application 08/818,688. Granted 6/30/1998
Note: Previously plaintiff sued Teva and Zydus on June 28, 2013.
Plaintiffs UCB Pharma actions relates to generics that they infringed one or more claims of the Reissued Patent No. RE 38,551 (“the ‘551 patent”) by filing the ANDA seeking approval for the commercial manufacture, use, offer for sale, sale and/or import of Vimapt before the expiration of the ’551 patent.
Patents in suit:
RE 38,551: “Anticonvulsant enantiomeric amino acid derivatives” by Kohn. Prosecuted by Scully, Scott, Murphy & Presser. Includes 13 claims (1 indep.). Was application 08/818,688. Granted 6/30/1998
Note: Previously plaintiff sued Teva and Zydus on June 28, 2013.